Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alnylam Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

63 comunicati stampa

Guarda tutti i comunicati
24/03/2026
Web e Social Network
Mercato del lavoro
Industria
Tecnica
Biotecnologia
Cardiologia
Sanità
Salute
Farmaceutica
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
10/03/2026
Finanza
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast TTR Investor Webinar
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
23/02/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/01/2026
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
17/12/2025
Industria
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/12/2025
Titoli e azioni
Biotecnologia
Farmaceutica
Salute
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/12/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Alnylam Pharmaceuticals Announces Changes to Board of Directors
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0